Oncology
antibodies

Antibody drug conjugates – The time is now

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs ca

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

Patients
Anatomical graphic concept of a liver in 3D

Rewriting the MASLD playbook

Effective care now requires identifying metabolic risks early and addressing the broader factors driving liver damage.

R&D